Suppr超能文献

实用临床试验研究监督的协调与简化

Harmonization and streamlining of research oversight for pragmatic clinical trials.

作者信息

O'Rourke P Pearl, Carrithers Judith, Patrick-Lake Bray, Rice Todd W, Corsmo Jeremy, Hart Raffaella, Drezner Marc K, Lantos John D

机构信息

Human Research Affairs, Partners HealthCare, Boston, MA, USA

School of Medicine, Johns Hopkins University, Baltimore, MD, USA.

出版信息

Clin Trials. 2015 Oct;12(5):449-56. doi: 10.1177/1740774515597685. Epub 2015 Sep 15.

Abstract

The oversight of research involving human participants is a complex process that requires institutional review board review as well as multiple non-institutional review board institutional reviews. This multifaceted process is particularly challenging for multisite research when each site independently completes all required local reviews. The lack of inter-institutional standardization can result in different review outcomes for the same protocol, which can delay study operations from start-up to study completion. Hence, there have been strong calls to harmonize and thus streamline the research oversight process. Although the institutional review board is only one of the required reviews, it is often identified as the target for harmonization and streamlining. Data regarding variability in decision-making and interpretation of the regulations across institutional review boards have led to a perception that variability among institutional review boards is a primary contributor to the problems with review of multisite research. In response, many researchers and policymakers have proposed the use of a single institutional review board of record, also called a central institutional review board, as an important remedy. While this proposal has merit, the use of a central institutional review board for multisite research does not address the larger problem of completing non-institutional review board institutional review in addition to institutional review board review—and coordinating the interdependence of these reviews. In this article, we describe the overall research oversight process, distinguish between institutional review board and institutional responsibilities, and identify challenges and opportunities for harmonization and streamlining. We focus on procedural and organizational issues and presume that the protection of human subjects remains the paramount concern. Suggested modifications of institutional review board processes that focus on time, efficiency, and consistency of review must also address what effect such changes have on the quality of review. We acknowledge that assessment of quality is difficult in that quality metrics for institutional review board review remain elusive. At best, we may be able to assess the time it takes to review protocols and the consistency across institutions.

摘要

对涉及人类受试者的研究进行监督是一个复杂的过程,需要机构审查委员会的审查以及多个非机构审查委员会的机构审查。当每个研究地点独立完成所有所需的当地审查时,这个多方面的过程对于多地点研究来说尤其具有挑战性。机构间缺乏标准化可能导致同一方案产生不同的审查结果,这可能会延误从研究启动到完成的整个研究操作过程。因此,人们强烈呼吁协调并简化研究监督过程。虽然机构审查委员会只是所需审查之一,但它常常被视为协调和简化的目标。关于各机构审查委员会在决策和法规解释方面存在差异的数据,导致人们认为机构审查委员会之间的差异是多地点研究审查问题的主要原因。对此,许多研究人员和政策制定者提议使用单一的记录机构审查委员会,也称为中央机构审查委员会,作为一项重要的补救措施。虽然这一提议有其优点,但在多地点研究中使用中央机构审查委员会并不能解决除机构审查委员会审查之外完成非机构审查委员会机构审查以及协调这些审查之间相互依存关系这个更大的问题。在本文中,我们描述了整体的研究监督过程,区分了机构审查委员会和机构的职责,并确定了协调和简化过程中的挑战与机遇。我们关注程序和组织问题,并假定保护人类受试者仍然是首要关注点。针对机构审查委员会程序提出的侧重于审查时间、效率和一致性的修改建议,也必须考虑这些变化对审查质量有何影响。我们承认评估质量很困难,因为机构审查委员会审查的质量指标仍然难以捉摸。充其量,我们也许能够评估审查方案所需的时间以及各机构之间的一致性。

相似文献

1
Harmonization and streamlining of research oversight for pragmatic clinical trials.
Clin Trials. 2015 Oct;12(5):449-56. doi: 10.1177/1740774515597685. Epub 2015 Sep 15.
2
American Society of Clinical Oncology policy statement: oversight of clinical research.
J Clin Oncol. 2003 Jun 15;21(12):2377-86. doi: 10.1200/JCO.2003.04.026. Epub 2003 Apr 29.
3
Oversight on the borderline: Quality improvement and pragmatic research.
Clin Trials. 2015 Oct;12(5):457-66. doi: 10.1177/1740774515597682. Epub 2015 Sep 15.
4
Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials.
Clin Trials. 2015 Oct;12(5):485-93. doi: 10.1177/1740774515597687. Epub 2015 Sep 15.
6
Gatekeepers for pragmatic clinical trials.
Clin Trials. 2015 Oct;12(5):442-8. doi: 10.1177/1740774515597699. Epub 2015 Sep 15.
8
Exploring the ethical and regulatory issues in pragmatic clinical trials.
Clin Trials. 2015 Oct;12(5):436-41. doi: 10.1177/1740774515598334. Epub 2015 Sep 15.

引用本文的文献

1
Methods for pragmatic randomized clinical trials of pain therapies: IMMPACT statement.
Pain. 2024 Oct 1;165(10):2165-2183. doi: 10.1097/j.pain.0000000000003249. Epub 2024 May 3.
4
What went right during the COVID crisis: The capabilities of local actors and lasting innovations in oncology care and research.
PLOS Glob Public Health. 2023 Sep 25;3(9):e0002366. doi: 10.1371/journal.pgph.0002366. eCollection 2023.
5
Pragmatic clinical trial design in emergency medicine: Study considerations and design types.
Acad Emerg Med. 2022 Oct;29(10):1247-1257. doi: 10.1111/acem.14513. Epub 2022 May 22.
6
Justice and equity in pragmatic clinical trials: Considerations for pain research within integrated health systems.
Learn Health Syst. 2021 Oct 19;6(2):e10291. doi: 10.1002/lrh2.10291. eCollection 2022 Apr.
7
Ethical and epistemic issues in the design and conduct of pragmatic stepped-wedge cluster randomized clinical trials.
Contemp Clin Trials. 2022 Apr;115:106703. doi: 10.1016/j.cct.2022.106703. Epub 2022 Feb 15.
8
Responding to signals of mental and behavioral health risk in pragmatic clinical trials: Ethical obligations in a healthcare ecosystem.
Contemp Clin Trials. 2022 Feb;113:106651. doi: 10.1016/j.cct.2021.106651. Epub 2022 Jan 5.

本文引用的文献

1
Cycle Time Metrics for Multisite Clinical Trials in the United States.
Ther Innov Regul Sci. 2013 Mar;47(2):152-160. doi: 10.1177/2168479012464371.
2
Ethical responsibilities toward indirect and collateral participants in pragmatic clinical trials.
Clin Trials. 2015 Oct;12(5):476-84. doi: 10.1177/1740774515597698. Epub 2015 Sep 15.
3
Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials.
Clin Trials. 2015 Oct;12(5):485-93. doi: 10.1177/1740774515597687. Epub 2015 Sep 15.
4
Privacy and confidentiality in pragmatic clinical trials.
Clin Trials. 2015 Oct;12(5):520-9. doi: 10.1177/1740774515597677. Epub 2015 Sep 15.
5
Use of altered informed consent in pragmatic clinical research.
Clin Trials. 2015 Oct;12(5):494-502. doi: 10.1177/1740774515597688. Epub 2015 Sep 15.
6
Exploring the ethical and regulatory issues in pragmatic clinical trials.
Clin Trials. 2015 Oct;12(5):436-41. doi: 10.1177/1740774515598334. Epub 2015 Sep 15.
7
The concept of risk in comparative effectiveness research.
N Engl J Med. 2015 Feb 26;372(9):884. doi: 10.1056/NEJMc1415933.
8
Nanostructured sensors for biomedical applications--a current perspective.
Curr Opin Biotechnol. 2015 Aug;34:118-24. doi: 10.1016/j.copbio.2014.11.019. Epub 2015 Jan 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验